NEWS ARTICLE
LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 2020
LEO Pharma net sales recovered from COVID-19 impact during the year, reaching DKK 10.1 billion (-6%).
Ballerup, Denmark, March 23, 2021
Read the full storyALL NEWS
- 6-22-2021 LEO Pharma announces European Commission approval of Adtralza® (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
- 3-22-2021 LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 2020
- 12-15-2020 LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development
- 10-27-2020 LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day
- 9-22-2020 LEO Pharma strengthens global leadership team with appointment of new Executive Vice President, Global Therapeutic & Value Strategy
- 8-30-2020 LEO Pharma sells portfolio of four products to Cheplapharm
- 8-19-2020 LEO Pharma unveils ambitious 2030 strategy positioning itself for long-term growth driven by innovation
- 8-18-2020 LEO Pharma strengthens global leadership team with appointment of new EVP People & Communications
- 6-29-2020 LEO Pharma strengthens global leadership team
- 3-12-2020 Updates regarding COVID-19
- 11-20-2019 LEO Pharma launches Open Innovation in Ontario to support the innovation ecosystem in the province
- 11-18-2019 LEO Pharma launches Open Innovation program and partnership with the University of Victoria in Canada
- 11-13-2019 Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors
- 11-06-2019 LEO Science & Tech Hub and Epicore Biosystems Announce Second Phase of Partnership
- 10-29-2019 LEO Pharma enters into option agreement with Ubiquigent for access to novel compounds
- 10-23-2019 World Psoriasis Day 2019: LEO Pharma launches new campaign to reduce the stigma surrounding psoriasis
- 6-30-2019 LEO Pharma completes the acquisition of Bayer’s prescription dermatology business
- 6-02-2019 LEO Pharma appoints Catherine Mazzacco as new CEO
- 5-09-2019 LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
- 4-10-2019 LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
- 4-08-2019 LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
- 3-18-2019 LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment
MEDIA ENQUIRIES
